# Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

> **NCT01861613** · PHASE4 · COMPLETED · sponsor: **Hui Zhuang** · enrollment: 2040 (actual)

## Conditions studied

- Hepatitis B
- Immune Response
- Seroprevalence

## Interventions

- **BIOLOGICAL:** HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)

## Key facts

- **NCT ID:** NCT01861613
- **Lead sponsor:** Hui Zhuang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 2040 (ACTUAL)
- **Last updated:** 2013-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861613, "Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01861613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*